A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study

Diana F. Nelson; Marie Diener-West; Alan S. Weinstein; David Schoenfeld; James S. Nelson; William T. Sause; Chu Huai Chang; Robert Goodman; Steven Carabell

doi:10.1016/0360-3016(86)90321-4

A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study

Diana F. Nelson, Marie Diener-West, Alan S. Weinstein, David Schoenfeld, James S. Nelson, William T. Sause, Chu Huai Chang, Robert Goodman, Steven Carabell

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m²/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m² once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m² of BCNU.

Original language	English (US)
Pages (from-to)	1793-1800
Number of pages	8
Journal	International journal of radiation oncology, biology, physics
Volume	12
Issue number	10
DOIs	https://doi.org/10.1016/0360-3016(86)90321-4
State	Published - Oct 1986
Externally published	Yes

Keywords

BCNU
Malignant glioma
Misonidazole
Radiation sensitizers
Radiation therapy

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0360-3016(86)90321-4

Cite this

Nelson, D. F., Diener-West, M., Weinstein, A. S., Schoenfeld, D., Nelson, J. S., Sause, W. T., Chang, C. H., Goodman, R., & Carabell, S. (1986). A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. International journal of radiation oncology, biology, physics, 12(10), 1793-1800. https://doi.org/10.1016/0360-3016(86)90321-4

A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. / Nelson, Diana F.; Diener-West, Marie; Weinstein, Alan S. et al.
In: International journal of radiation oncology, biology, physics, Vol. 12, No. 10, 10.1986, p. 1793-1800.

Research output: Contribution to journal › Article › peer-review

Nelson, DF, Diener-West, M, Weinstein, AS, Schoenfeld, D, Nelson, JS, Sause, WT, Chang, CH, Goodman, R & Carabell, S 1986, 'A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study', International journal of radiation oncology, biology, physics, vol. 12, no. 10, pp. 1793-1800. https://doi.org/10.1016/0360-3016(86)90321-4

Nelson DF, Diener-West M, Weinstein AS, Schoenfeld D, Nelson JS, Sause WT et al. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. International journal of radiation oncology, biology, physics. 1986 Oct;12(10):1793-1800. doi: 10.1016/0360-3016(86)90321-4

@article{3e2b1651718041739650f7691fc21d59,

title = "A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study",

abstract = "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.",

keywords = "BCNU, Malignant glioma, Misonidazole, Radiation sensitizers, Radiation therapy",

author = "Nelson, {Diana F.} and Marie Diener-West and Weinstein, {Alan S.} and David Schoenfeld and Nelson, {James S.} and Sause, {William T.} and Chang, {Chu Huai} and Robert Goodman and Steven Carabell",

note = "Funding Information: This investigation was supported by Grant Number CA 2 166 l-07, awarded by the National Cancer Institute, DHHS. Presented at the Eighteenth Annual ASCO meeting in St. Louis, MO, April 25-27, 1982. Reprint requests to: Dr. Diana F. Nelson, Department of Radiation Therapy, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19 104.",

year = "1986",

month = oct,

doi = "10.1016/0360-3016(86)90321-4",

language = "English (US)",

volume = "12",

pages = "1793--1800",

journal = "International journal of radiation oncology, biology, physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery

T2 - Final report of an RTOG study

AU - Nelson, Diana F.

AU - Diener-West, Marie

AU - Weinstein, Alan S.

AU - Schoenfeld, David

AU - Nelson, James S.

AU - Sause, William T.

AU - Chang, Chu Huai

AU - Goodman, Robert

AU - Carabell, Steven

N1 - Funding Information: This investigation was supported by Grant Number CA 2 166 l-07, awarded by the National Cancer Institute, DHHS. Presented at the Eighteenth Annual ASCO meeting in St. Louis, MO, April 25-27, 1982. Reprint requests to: Dr. Diana F. Nelson, Department of Radiation Therapy, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19 104.

PY - 1986/10

Y1 - 1986/10

N2 - This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

AB - This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. One hundred and forty-six evaluable patients were treated with conventional radiation therapy to 60.00 Gy in 6-7 weeks plus BCNU 80 mg/m2/d for 3 days every 8 weeks (XRT + BCNU). One hundred and forty-seven evaluable patients were treated with misonidazole 2.5 gm/m2 once a week for 6 weeks, radiation therapy to 60 Gy and BCNU (MISO + XRT + BCNU). Patients were stratified according to the prognostic factors of age, performance status, and histology. Distribution of these characteristics was comparable among the treatment groups. The median survival for XRT + BCNU was 55.0 weeks, and for MISO + XRT + BCNU 46.0 weeks (p = 0.35). With patients on a minimum dose of dexamethasone of 3 mg/d, misonidazole neurotoxicity included 8.8% peripheral neuropathy, 2.7% CNS toxicity, and a 0.68% ototoxicity. BNCU pulmonary toxicity occurred in 9.3% of patients who received 902-2062 mg/m2 of BCNU.

KW - BCNU

KW - Malignant glioma

KW - Misonidazole

KW - Radiation sensitizers

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0022997570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022997570&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(86)90321-4

DO - 10.1016/0360-3016(86)90321-4

M3 - Article

C2 - 3531110

AN - SCOPUS:0022997570

SN - 0360-3016

VL - 12

SP - 1793

EP - 1800

JO - International journal of radiation oncology, biology, physics

JF - International journal of radiation oncology, biology, physics

IS - 10

ER -

A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this